Recent GRI News
- GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results • GlobeNewswire Inc. • 05/22/2025 12:00:00 PM
- GRI Bio to Participate in the Virtual Investor Closing Bell Series • GlobeNewswire Inc. • 05/21/2025 01:15:00 PM
- GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase • GlobeNewswire Inc. • 05/16/2025 01:15:00 PM
- GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 • GlobeNewswire Inc. • 05/15/2025 12:35:00 PM
- GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) • GlobeNewswire Inc. • 05/08/2025 12:45:00 PM
- GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) • GlobeNewswire Inc. • 05/07/2025 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2025 11:35:49 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/05/2025 11:35:23 AM
- GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference • GlobeNewswire Inc. • 04/16/2025 12:35:00 PM
- GRI Bio Announces Closing of $5.0 Million Public Offering • GlobeNewswire Inc. • 04/02/2025 08:05:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 04/02/2025 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2025 12:29:59 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/02/2025 04:15:28 AM
- GRI Bio Announces Pricing of $5.0 Million Public Offering • GlobeNewswire Inc. • 04/01/2025 03:15:00 PM
- GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) • GlobeNewswire Inc. • 04/01/2025 01:00:00 PM
- GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan • GlobeNewswire Inc. • 03/31/2025 12:00:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/26/2025 07:11:11 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/25/2025 10:21:58 AM
- GRI Bio Participates in a Virtual Investor CEO Connect Segment • GlobeNewswire Inc. • 03/18/2025 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2025 12:06:41 PM
- GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) • GlobeNewswire Inc. • 03/17/2025 12:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/14/2025 09:00:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2025 12:37:05 PM
- GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule • GlobeNewswire Inc. • 03/11/2025 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2025 09:08:43 PM
FEATURED Cannabix Technologies Receives Notice of Allowance from USPTO for Contactless Breath Analysis • Jun 17, 2025 8:00 AM
Avant Technologies' JV Partner, Ainnova, Begins Diabetic Retinopathy Screenings with Leading Pharmacies • AVAI • Jun 17, 2025 8:00 AM
A.R.T. Digital Holdings (OTC: CGAC) Secures Non-Dilutive Financing for George West Site Supporting NASDAQ: BTBT • CGAC • Jun 17, 2025 5:07 AM
VAYK to Acquire Up to $9 million in Time-share Vacation Properties Through Non-Cash Deals • VAYK • Jun 11, 2025 9:45 AM
ECGI Holdings Invests in AI-Powered Fantasy Sports Startup Payday Fantasy • ECGI • Jun 10, 2025 8:30 AM
Avant Technologies Signs Letter of Intent for a Business Combination • AVAI • Jun 10, 2025 8:00 AM